This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): celecoxib, Celecox, YM177, Onsenal (EU)
Description: Celebrex is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities. It inhibits prostaglandin synthesis by selectively inhibiting cyclooxygenase-2 (COX-2).
Deal Structure: In Japan, Pharmacia K.K. and Yamanouchi jointly developed celecoxib. After receiving regulatory approval, the two companies will co-promote celecoxib with a single brand name while Pharmacia K.K. will import bulk material and Yamanouchi will manufacture and distribute the finished product. Pharmacia and Yamanouchi are now owned by Pfizer and Astellas Pharma, respectively.
Partners: Astellas Pharma, Inc.
Pink Sheet Celebrex Clinical Protocol
Pink Sheet Celebrex FDA Reviewers
Additional information available to subscribers only: